Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
· cnbc.com
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
Pfizer Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Wednesday, March 4, 2026.
Pfizer on Tuesday reported second-quarter ...